688166 博瑞医药
已收盘 10-23 15:00:00
资讯
新帖
简况
大健康“A+H”退潮，谁还能上桌？
蓝鲸财经 · 10-15
大健康“A+H”退潮，谁还能上桌？
博瑞医药（688166）10月13日主力资金净卖出753.89万元
证券之星 · 10-14
博瑞医药（688166）10月13日主力资金净卖出753.89万元
股市必读：博瑞医药新发布《自愿披露关于BGM0504片获得药物临床试验批准通知书的公告》
证券之星 · 10-14
股市必读：博瑞医药新发布《自愿披露关于BGM0504片获得药物临床试验批准通知书的公告》
股市必读：博瑞医药新发布《自愿披露关于BGM0504片获得药物临床试验批准通知书的公告》
证券之星 · 10-13
股市必读：博瑞医药新发布《自愿披露关于BGM0504片获得药物临床试验批准通知书的公告》
博瑞医药最新公告：BGM0504片获药物临床试验批准通知书
证券之星 · 10-12
博瑞医药最新公告：BGM0504片获药物临床试验批准通知书
博瑞医药（688166）10月8日主力资金净卖出737.33万元
证券之星 · 10-09
博瑞医药（688166）10月8日主力资金净卖出737.33万元
10月8日博瑞医药跌6.65%，科创创新药ETF国泰基金重仓该股
证券之星 · 10-08
10月8日博瑞医药跌6.65%，科创创新药ETF国泰基金重仓该股
博瑞医药BGM0504减重Ⅲ期数据亮相EASD 2026，纪立农教授LBA口头报告从52周减重到心血管代谢获益
同花顺 · 10-03
博瑞医药BGM0504减重Ⅲ期数据亮相EASD 2026，纪立农教授LBA口头报告从52周减重到心血管代谢获益
博瑞医药：终止发行H股股票并在港交所主板上市
同花顺 · 09-30
博瑞医药：终止发行H股股票并在港交所主板上市
“药二代”密集走向台前，大多拥有海外名校背景，将如何接好“转型”这一棒？
红星资本局 · 09-22
“药二代”密集走向台前，大多拥有海外名校背景，将如何接好“转型”这一棒？
每周股票复盘：博瑞生物医药（688166）股东减持547.33万股致股本变动
证券之星 · 09-20
每周股票复盘：博瑞生物医药（688166）股东减持547.33万股致股本变动
9月17日博瑞医药发布公告，股东减持547.33万股
证券之星 · 09-17
9月17日博瑞医药发布公告，股东减持547.33万股
博瑞医药：硫酸阿托品滴眼液的《药物临床试验批准通知书》转让给宁波视方医药科技有限公司
证券之星 · 09-16
博瑞医药：硫酸阿托品滴眼液的《药物临床试验批准通知书》转让给宁波视方医药科技有限公司
每周股票复盘：博瑞医药（688166）将参加科创板业绩说明会
证券之星 · 09-13
每周股票复盘：博瑞医药（688166）将参加科创板业绩说明会
股市必读：博瑞医药新发布《关于参加2026年半年度科创板创新药行业集体业绩说明会的公告》
证券之星 · 09-09
股市必读：博瑞医药新发布《关于参加2026年半年度科创板创新药行业集体业绩说明会的公告》
9月7日博瑞医药涨7.07%，科创创新药ETF国泰基金重仓该股
证券之星 · 09-07
9月7日博瑞医药涨7.07%，科创创新药ETF国泰基金重仓该股
博瑞医药（688166）2026年中报简析：营收净利润同比双双增长，应收账款上升
证券之星 · 09-01
博瑞医药（688166）2026年中报简析：营收净利润同比双双增长，应收账款上升
博瑞医药（688166）披露2026年半年度报告，8月31日股价上涨4.41%
证券之星 · 08-31
博瑞医药（688166）披露2026年半年度报告，8月31日股价上涨4.41%
博瑞医药(688166.SH)发布上半年业绩，归母净利润5893.28万元，同比增长243.17%
智通财经 · 08-30
博瑞医药(688166.SH)发布上半年业绩，归母净利润5893.28万元，同比增长243.17%
博瑞医药(688166)6月30日股东户数2.1万户，较上期增加2.94%
证券之星 · 08-30
博瑞医药(688166)6月30日股东户数2.1万户，较上期增加2.94%
加载更多
公司概况
公司名称：
博瑞生物医药(苏州)股份有限公司
所属行业：
医药制造业
上市日期：
2019-11-08
主营业务：
博瑞生物医药(苏州)股份有限公司的主营业务是医药中间体、原料药和制剂产品的研发、生产。公司的主要产品是创新药BGM0504、BGM1812、恩替卡韦、奥司他韦、卡泊芬净、米卡芬净钠、阿尼芬净、泊沙康唑、依维莫司、吡美莫司、布地奈德、沙美特罗替卡松、噻托溴铵、艾立布林、芦比替定。
发行价格：
12.71
{"stockData":{"symbol":"688166","market":"SH","secType":"STK","nameCN":"博瑞医药","latestPrice":31.95,"timestamp":1792738800000,"preClose":30.7,"halted":0,"volume":9921501,"delay":0,"changeRate":0.0407,"floatShares":436000000,"shares":436000000,"eps":0.221,"marketStatus":"已收盘","change":1.25,"latestTime":"10-23 15:00:00","open":30.31,"high":32.12,"low":29.55,"amount":305000000,"amplitude":0.0837,"askPrice":31.95,"askSize":188,"bidPrice":31.92,"bidSize":18,"shortable":0,"etf":0,"ttmEps":0.221,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792978200000},"marketStatusCode":5,"adr":0,"adjPreClose":30.7,"symbolType":"stock_kcb","openAndCloseTimeList":[[1792719000000,1792726200000],[1792731600000,1792738800000]],"highLimit":33.77,"lowLimit":27.63,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":435794991,"isCdr":false,"pbRate":4.56,"roa":"--","peRate":144.570136,"roe":"2.19%","epsLYR":0.13,"committee":-0.816393,"marketValue":13924000000,"turnoverRate":0.0228,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-10-26。","afterMarket":{"amount":31950,"volume":1000,"close":31.95,"buyVolume":0,"sellVolume":2296,"time":1792740837746,"indexStatus":"已收盘 10-23 15:30:00","preClose":30.7},"floatMarketCap":13924000000},"requestUrl":"/m/hq/s/688166","defaultTab":"news","newsList":[{"id":"2675619300","title":"大健康“A+H”退潮，谁还能上桌？","url":"https://stock-news.laohu8.com/highlight/detail?id=2675619300","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675619300?lang=zh_cn&edition=full","pubTime":"2026-10-15 17:16","pubTimestamp":1792055774,"startTime":"0","endTime":"0","summary":"2026年以来，A股大健康上市公司的赴港上市明显降温。可以说，港股终止上市也没有与该风波有直接关联。该企业负债率约25%，因此市场猜测“A+H”上市的诉求并非缺钱续命，而是全球化战略布局。头部医疗器械、创新药龙头持续坚守“A+H”双平台战略，持续获得机构认可，港股上市成为全球化发展的配套工具。归根结底，大健康板块的“A+H”上市潮退是行情、规则、企业基本面三重因素叠加的结果。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1792043506360832246","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["IE0005HP3H50.USD","LU0823426308.USD","LU1979443071.USD","LU1734074674.USD","BK0229","LU0084288322.USD","LU2148510915.USD","LU1997245177.USD","688639","LU0605514214.HKD","LU0594300179.USD","LU0594300419.USD","LU0650527681.SGD","LU2488822045.USD","LU1064130708.USD","BK4588","SGXZ49509284.SGD","688166","IE00B031HY20.USD","LU1934453819.USD","IE0008368742.USD","BK0251","LU0572944931.SGD","LU1688375341.USD","IPOS","LU1146622755.USD","LU1655091616.SGD","LU2213484517.USD","IE00B29SXG58.USD","VXUS","LU0359202008.SGD","LU0823426480.USD","LU1997245094.SGD","LU2424517915.HKD","IE0031814852.USD","LU1781817850.SGD","KCAI","LU0359201612.USD","688506","SGXZ81163826.USD","BK4585","688266","LU2348774022.SGD","LU0327786744.USD","LU1064131003.USD","IE00B031J352.USD","LU2348773727.SGD","LU0405327148.USD","300760","LU1820825898.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675395780","title":"博瑞医药（688166）10月13日主力资金净卖出753.89万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675395780","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675395780?lang=zh_cn&edition=full","pubTime":"2026-10-14 08:24","pubTimestamp":1791937496,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月13日收盘，博瑞医药报收于31.05元，下跌3.78%，换手率2.01%，成交量8.77万手，成交额2.74亿元。近5日资金流向一览见下表：博瑞医药融资融券信息显示，融资方面，当日融资买入2575.91万元，融资偿还3460.77万元，融资净偿还884.86万元。博瑞医药主营业务：原料药、医药中间体和制剂的研发、生产和销售及提供相关技术转让。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400007152.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675692993","title":"股市必读：博瑞医药新发布《自愿披露关于BGM0504片获得药物临床试验批准通知书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2675692993","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675692993?lang=zh_cn&edition=full","pubTime":"2026-10-14 01:53","pubTimestamp":1791913989,"startTime":"0","endTime":"0","summary":"公司公告汇总：全资子公司收到BGM0504片药物临床试验批准通知书，该药为全球尚无同类靶点口服剂型获批上市的GLP-1/GIP双重激动剂。公司公告汇总自愿披露关于BGM0504片获得药物临床试验批准通知书的公告博瑞生物医药（苏州）股份有限公司全资子公司博瑞制药（苏州）有限公司收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意BGM0504片在成人2型糖尿病患者中开展临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400001656.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675740801","title":"股市必读：博瑞医药新发布《自愿披露关于BGM0504片获得药物临床试验批准通知书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2675740801","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675740801?lang=zh_cn&edition=full","pubTime":"2026-10-13 01:16","pubTimestamp":1791825375,"startTime":"0","endTime":"0","summary":"公司公告汇总：博瑞医药全资子公司收到BGM0504片药物临床试验批准通知书，该药为全球尚无同类靶点获批上市的GLP-1/GIP双重激动剂口服剂型。公司公告汇总自愿披露关于BGM0504片获得药物临床试验批准通知书的公告博瑞生物医药（苏州）股份有限公司全资子公司博瑞制药（苏州）有限公司收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意BGM0504片在成人2型糖尿病患者中开展临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101300001640.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674877125","title":"博瑞医药最新公告：BGM0504片获药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2674877125","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674877125?lang=zh_cn&edition=full","pubTime":"2026-10-12 20:10","pubTimestamp":1791807042,"startTime":"0","endTime":"0","summary":"博瑞医药(688166.SH)公告称，公司全资子公司博瑞制药近日收到国家药监局签发的《药物临床试验批准通知书》，同意BGM0504片在成人2型糖尿病患者中开展临床试验。BGM0504是公司自主研发的GLP-1和GIP受体双重激动剂，其口服剂型全球尚无同类靶点获批上市。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200031379.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674899918","title":"博瑞医药（688166）10月8日主力资金净卖出737.33万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674899918","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674899918?lang=zh_cn&edition=full","pubTime":"2026-10-09 08:29","pubTimestamp":1791505775,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月8日收盘，博瑞医药报收于33.43元，下跌6.65%，换手率3.01%，成交量13.1万手，成交额4.47亿元。近5日资金流向一览见下表：博瑞医药融资融券信息显示，融资方面，当日融资买入7090.05万元，融资偿还3053.0万元，融资净买入4037.06万元。博瑞医药主营业务：原料药、医药中间体和制剂的研发、生产和销售及提供相关技术转让。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900006161.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673220530","title":"10月8日博瑞医药跌6.65%，科创创新药ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2673220530","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673220530?lang=zh_cn&edition=full","pubTime":"2026-10-08 16:37","pubTimestamp":1791448656,"startTime":"0","endTime":"0","summary":"证券之星消息，10月8日博瑞医药跌6.65%，收盘报33.43元，换手率3.01%，成交量13.1万手，成交额4.47亿元。重仓博瑞医药的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为国泰基金的科创创新药ETF国泰。科创创新药ETF国泰的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800021274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","589720","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672069742","title":"博瑞医药BGM0504减重Ⅲ期数据亮相EASD 2026，纪立农教授LBA口头报告从52周减重到心血管代谢获益","url":"https://stock-news.laohu8.com/highlight/detail?id=2672069742","media":"同花顺","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2672069742?lang=zh_cn&edition=full","pubTime":"2026-10-03 10:20","pubTimestamp":1790994000,"startTime":"0","endTime":"0","summary":"2026年9月28日至10月2日，第62届欧洲糖尿病研究协会年会(EASD2026)在意大利米兰举行。博瑞医药自主研发的GLP-1/GIP受体双重激动剂BGM0504注射液，治疗中国超重或肥胖人群的Ⅲ期临床研究，入 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261003/c680435805.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261003/c680435805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK0239","688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671127214","title":"博瑞医药：终止发行H股股票并在港交所主板上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2671127214","media":"同花顺","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671127214?lang=zh_cn&edition=full","pubTime":"2026-09-30 16:58","pubTimestamp":1790758680,"startTime":"0","endTime":"0","summary":"9月30日，博瑞医药(688166.SH)公告称，公司此前曾审议通过发行H股股票并在香港联交所主板上市的相关议案，鉴于前次申报将于近日到期，结合自身实际情况及境内外资本市场环境变化等因素，经 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260930/c680414474.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260930/c680414474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0239","688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669234144","title":"“药二代”密集走向台前，大多拥有海外名校背景，将如何接好“转型”这一棒？","url":"https://stock-news.laohu8.com/highlight/detail?id=2669234144","media":"红星资本局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669234144?lang=zh_cn&edition=full","pubTime":"2026-09-22 20:16","pubTimestamp":1790079360,"startTime":"0","endTime":"0","summary":"红星资本局注意到，“药二代”们正密集走向台前。与“创一代”不同的是，他们大多拥有海外名校背景，进入核心管理层的方式也各不相同。今年以来，还有多位“药二代”走向台前。多家药企处于业务转型期二代接棒或面临考验值得一提的是，近期迎来“药二代”上台的上市公司，多数处于业务转型期。“药二代”走向前台，企业如何完成转型，仍有待时间验证。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2026-09-22/doc-inistexc1956967.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1008478684.HKD","LU0880133367.SGD","KURE","LU1226287529.USD","LU0501845795.SGD","LU0140636845.USD","LU0315179316.USD","LU1226288170.HKD","HK0000165453.HKD","IE0008369823.USD","LU1813983027.USD","LU1993786604.SGD","BK0046","01093","LU1960683339.HKD","600380","LU1328277881.USD","LU2039709279.SGD","300453","000513","LU0314109678.HKD","LU0067412154.USD","LU1226287792.SGD","IE00B031HY20.USD","SG9999004220.SGD","BK0251","IE00BZ08YS42.EUR","688166","BK0077","BK0102","LU0072913022.USD","IE00BZ08YT58.USD","300298","LU0326950275.SGD","BK0239","BK0187","LU1951186391.HKD","IE00B543WZ88.USD","LU1152091754.HKD","BK0028","IE00BZ08YR35.GBP","BK0114","IE0008368742.USD","LU1807302812.USD","BK1191","BK1521","LU1152091168.USD","LU1226287875.USD","BK0188","LU1226288253.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668906916","title":"每周股票复盘：博瑞生物医药（688166）股东减持547.33万股致股本变动","url":"https://stock-news.laohu8.com/highlight/detail?id=2668906916","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668906916?lang=zh_cn&edition=full","pubTime":"2026-09-20 01:07","pubTimestamp":1789837632,"startTime":"0","endTime":"0","summary":"截至2026年9月18日收盘，博瑞生物医药报收于35.03元，较上周的35.23元下跌0.57%。本周，博瑞生物医药9月18日盘中最高价报36.15元。博瑞生物医药当前最新总市值152.66亿元，在化学制药板块市值排名27/149，在两市A股市值排名1261/5220。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092000000071.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239","399441","161726"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668921965","title":"9月17日博瑞医药发布公告，股东减持547.33万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2668921965","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668921965?lang=zh_cn&edition=full","pubTime":"2026-09-17 18:01","pubTimestamp":1789639263,"startTime":"0","endTime":"0","summary":"证券之星消息，9月17日博瑞医药发布公告《博瑞医药:股东减持股份结果公告》，其股东先进制造产业投资基金(有限合伙)于2026年6月18日至2026年9月17日间合计减持547.33万股，占公司目前总股本的1.2559%，变动期间该股股价下跌14.31%，截止9月17日收盘报34.6元。股东增减持详情见下表：根据博瑞医药2026年中报公布的十大股东详情如下：本文数据来源于博瑞医药公告，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091700029781.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667602583","title":"博瑞医药：硫酸阿托品滴眼液的《药物临床试验批准通知书》转让给宁波视方医药科技有限公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2667602583","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667602583?lang=zh_cn&edition=full","pubTime":"2026-09-16 18:12","pubTimestamp":1789553530,"startTime":"0","endTime":"0","summary":"证券之星消息，博瑞医药(688166)09月16日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘：贵公司的硫酸阿托品滴眼液的临床是暂停了吗？大约何时能出临床数据？博瑞医药回复：尊敬的投资者您好！公司2022年年度报告披露，硫酸阿托品滴眼液取得了药物临床试验批准通知书，且公司已将硫酸阿托品滴眼液的《药物临床试验批准通知书》转让给宁波视方医药科技有限公司。感谢您的关注，谢谢！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091600029004.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","159938","688166","BK1515","BK1574","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667550030","title":"每周股票复盘：博瑞医药（688166）将参加科创板业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2667550030","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667550030?lang=zh_cn&edition=full","pubTime":"2026-09-13 03:09","pubTimestamp":1789240151,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，博瑞医药报收于35.23元，较上周的34.79元上涨1.26%。本周，博瑞医药9月8日盘中最高价报39.26元。本周关注点来自公司公告汇总：博瑞医药将参加2026年半年度科创板创新药行业集体业绩说明会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000929.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374138","title":"股市必读：博瑞医药新发布《关于参加2026年半年度科创板创新药行业集体业绩说明会的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374138","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666374138?lang=zh_cn&edition=full","pubTime":"2026-09-09 00:50","pubTimestamp":1788886225,"startTime":"0","endTime":"0","summary":"截至2026年9月8日收盘，博瑞医药报收于37.91元，上涨1.77%，换手率3.15%，成交量13.71万手，成交额5.19亿元。公司公告汇总：博瑞医药将于9月16日15:00–17:00参加上交所主办的科创板创新药行业集体业绩说明会，董事长、总经理袁建栋等高管将出席并接受网络文字互动提问。董事长、总经理袁建栋，财务总监詹春雷，独立董事许冬冬，董事会秘书李加宁将出席。投资者可于9月9日至9月15日16:00前通过上证路演中心或公司邮箱IR@bright-gene.com提前提问。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900002007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK0239","06978","BK1574","688166","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665316080","title":"9月7日博瑞医药涨7.07%，科创创新药ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2665316080","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665316080?lang=zh_cn&edition=full","pubTime":"2026-09-07 16:38","pubTimestamp":1788770331,"startTime":"0","endTime":"0","summary":"证券之星消息，9月7日博瑞医药涨7.07%，收盘报37.25元，换手率3.65%，成交量15.9万手，成交额5.81亿元。重仓博瑞医药的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为国泰基金的科创创新药ETF国泰。科创创新药ETF国泰的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700021114.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","589720","688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664885269","title":"博瑞医药（688166）2026年中报简析：营收净利润同比双双增长，应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2664885269","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664885269?lang=zh_cn&edition=full","pubTime":"2026-09-01 06:09","pubTimestamp":1788214181,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期博瑞医药发布2026年中报。截至本报告期末，公司营业总收入6.78亿元，同比上升26.17%，归母净利润5893.28万元，同比上升243.17%。按单季度数据看，第二季度营业总收入3.53亿元，同比上升22.42%，第二季度归母净利润4963.91万元，同比上升1078.12%。本报告期博瑞医药应收账款上升，应收账款同比增幅达50.25%。最近有知名机构关注了公司以下问题：问：答环节答：二、问环节本文数据来源于博瑞医药2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100004809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663079789","title":"博瑞医药（688166）披露2026年半年度报告，8月31日股价上涨4.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663079789","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663079789?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:43","pubTimestamp":1788169412,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘，博瑞医药报收于36.24元，较前一交易日上涨4.41%，最新总市值为157.93亿元。该股当日开盘36.34元，最高36.5元，最低34.91元，成交额达5.2亿元，换手率为3.34%。博瑞生物医药（苏州）股份有限公司于2026年8月31日披露《2026年半年度报告》。公告显示，截至报告期末，公司总资产为6,505,278,933.66元，较上年度末增长11.68%；归属于上市公司股东的净资产为3,052,325,774.52元，较上年度末增长21.07%。经营活动产生的现金流量净额为15,229,433.59元，同比减少86.60%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100024619.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663704907","title":"博瑞医药(688166.SH)发布上半年业绩，归母净利润5893.28万元，同比增长243.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663704907","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663704907?lang=zh_cn&edition=full","pubTime":"2026-08-30 17:44","pubTimestamp":1788083092,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博瑞医药 发布2026年半年度报告，报告期内，公司实现营业收入6.78亿元，同比增长26.17%。实现归属于上市公司股东的净利润5893.28万元，同比增长243.17%。主要系营业收入增长带来毛利额同比增长，营业收入的增长部分主要集中在高毛利产品上，导致整体利润上升明显。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489023.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"博瑞医药(688166.SH)发布上半年业绩，归母净利润5893.28万元，同比增长243.17%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663491070","title":"博瑞医药(688166)6月30日股东户数2.1万户，较上期增加2.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663491070","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663491070?lang=zh_cn&edition=full","pubTime":"2026-08-30 17:07","pubTimestamp":1788080863,"startTime":"0","endTime":"0","summary":"证券之星消息，近日博瑞医药披露，截至2026年6月30日公司股东户数为2.1万户，较3月31日增加599.0户，增幅为2.94%。在化学制药行业个股中，博瑞医药股东户数低于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.67万户。从股价来看，2026年3月31日至2026年6月30日，博瑞医药区间跌幅为27.74%，在此期间股东户数增加599.0户，增幅为2.94%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000011105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1792829916306,"stockEarnings":[{"period":"1week","weight":0.0336},{"period":"1month","weight":-0.1198},{"period":"3month","weight":-0.0822},{"period":"6month","weight":-0.4672},{"period":"1year","weight":-0.3841},{"period":"ytd","weight":-0.3485}],"compareEarnings":[{"period":"1week","weight":-0.0069},{"period":"1month","weight":-0.0625},{"period":"3month","weight":-0.0324},{"period":"6month","weight":-0.0954},{"period":"1year","weight":-0.0591},{"period":"ytd","weight":-0.0701}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"博瑞生物医药(苏州)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"20963人(较上一季度增加2.94%)","perCapita":"20788股","listingDate":"2019-11-08","address":"江苏省苏州市吴中区工业园区星湖街218号纳米科技园C25栋","registeredCapital":"43579万元","survey":" 博瑞生物医药(苏州)股份有限公司的主营业务是医药中间体、原料药和制剂产品的研发、生产。公司的主要产品是创新药BGM0504、BGM1812、恩替卡韦、奥司他韦、卡泊芬净、米卡芬净钠、阿尼芬净、泊沙康唑、依维莫司、吡美莫司、布地奈德、沙美特罗替卡松、噻托溴铵、艾立布林、芦比替定。","listedPrice":12.71},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博瑞医药(688166)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博瑞医药(688166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博瑞医药,688166,博瑞医药股票,博瑞医药股票老虎,博瑞医药股票老虎国际,博瑞医药行情,博瑞医药股票行情,博瑞医药股价,博瑞医药股市,博瑞医药股票价格,博瑞医药股票交易,博瑞医药股票购买,博瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博瑞医药(688166)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博瑞医药(688166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}